AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 immunotherapy for early Parkinson’s disease, showing a significant increase in anti-alpha-synuclein ...

Major Trial Looks at Most Effective Speech Therapy for People With Parkinson's Disease July 10, 2024 — A major clinical trial has shown the Lee Silverman Voice Treatment (LSVT LOUD ) is more ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

(Nature Genetics) A high dose of the investigational gene therapy AAV-GAD ... and showed improvement in motor scores in a small Parkinson's trial, MeiraGTx said. CVN424, a GPR6 inverse agonist ...

An oral presentation at the Michael J. Fox Foundation’s 16 th Annual Parkinson’s Disease Therapeutics Conference in October 2024 in New York, NY. A virtual webinar hosted by Gain Therapeutics in ...